Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA Study

Annals of Internal Medicine

Volumn 130, Issue 7, 1999, Pages 570-577

  Miller, Veronica ^a   Mocroft, Amanda ^b   Reiss, Peter ^c   Katlama, Christine ^d   Papadopoulos, Anthony I ^e   Katzenstein, Terese ^f   Van Lunzen, Jan ^g   Antunes, Francisco ^h   Phillips, Andrew N ^b   Lundgren, Jens D ⁱ  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Royal Free Centre for HIV Medicine   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e 1st IKA Hospital   (Greece)

^f Rigshospitalet   (Denmark)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h HOSPITAL DE SANTA MARIA   (Portugal)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; VIRUS LOAD;

EID: 0033528735     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-7-199904060-00005     Document Type: Article

References (16)

1. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changng incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11:1731-8.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-30.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
4. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales I, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:1528-33.
5. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-9.
6. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less AIDS Clinicai Trials Group 320 Study Team. N Engl J Med. 1997;337:725-33.
7. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996;173:321-9.
8. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-6.
9. Angel JB, Kumar A, Parato K, Filion LG, Diaz-Mitoma F, Daftarian P, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898-904.
10. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet. 1998;351:228-30.
11. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med. 1997; 127:922-46.
12. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54.
13. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med. 1997;126:939-45.
14. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996;335:1091-8.15.
15. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40-7.
16. Kirk O, Mocroft A, Katzenstein TL, Lazzarin A, Antunes F, Francioli P, et al. Changes n use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. AIDS. 1998;12:2031-9.